YIPF5

Across TCGA pan-cancer cohorts, YIPF5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YIPF5 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher YIPF5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated YIPF5 expression acts as an unfavorable survival marker.

LUAD, PDAC, and CCRCC are the cancer types where YIPF5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	9	view →
PDAC	OS	Tertile	IV	0.425	0.962	.024	3	view →
CCRCC	OS	Median	All	0.727	1.000	.025	3	view →
GBM	OS	Quartile	All	0.730	0.923	.018	3	view →
LSCC	DFS	Quartile	III,IV	0.382	0.867	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YIPF5–LUAD (DFS)

Open the LUAD breakdown →